What the research found
Researchers at the University of Chicago screened dietary compounds for senolytic activity—the ability to selectively kill senescent cells without harming healthy ones. Vanadyl sulfate (VS), a naturally occurring mineral found in foods like shellfish and mushrooms, emerged as a potent candidate. When administered to aged mice in drinking water for 13 weeks starting around 76 weeks of age, VS improved physical performance, body composition, glucose handling, and organ function markers. The treatment group also showed reduced levels of cellular senescence markers (SA-β-gal, p16, p21) and lower inflammatory gene expression.
In a lifespan study, male mice treated with VS from approximately 71 weeks of age for 90 days lived roughly 7.4% longer on average than controls, though the effect barely reached statistical significance in this small cohort. Notably, benefits persisted after treatment stopped—improvements in fitness and metabolic parameters remained even when mice returned to regular water, suggesting durable tissue-level changes rather than temporary physiological adjustments.
The mechanism involves VS acting as a mild oxidant that triggers protein stress specifically in senescent cells. Senescent cells accumulate oxidized glutathione and lack sufficient enzyme capacity to restore the antioxidant environment, making them vulnerable to VS-induced protein misfolding and cell death. Healthy cells tolerate the same oxidative stress without dying.
Why it matters for you
If validated, VS could represent a practical senolytic approach—unlike experimental senolytics requiring pharmaceutical development, it's already a supplement on shelves. For MyKine users tracking biomarkers, this matters most if you monitor inflammatory markers (CRP, IL-6) or glucose metabolism (fasting glucose, HbA1c, insulin sensitivity). The mice showed improvements in these areas, along with body composition changes that MyKine users typically track via DEXA or scale weight plus training performance.
The persistent benefits after treatment cessation are particularly interesting for protocol design. Rather than continuous dosing, intermittent senolytic interventions—if they work similarly in humans—might achieve lasting effects on tissue quality. This aligns with emerging interest in pulse-dosing approaches for peptides and other interventions targeting cellular aging.
However, translation to humans remains speculative. Mice treated at 71 weeks (roughly equivalent to human early-to-mid 60s) represent late-life intervention, and whether younger users would see lifespan benefit, or what optimal dosing and duration would look like, is entirely unknown.
Caveats
- Animal model only: All lifespan and most functional data come from mice; human translation is unproven
- Small cohort, marginal significance: Lifespan increase barely reached statistical significance in ~20 mice per group
- Female lifespan untested: Benefits were shown in females for endurance and metabolism, but not longevity
- Mechanism inferred, not proven: The withdrawal experiment suggests senescent cell removal but doesn't definitively prove it
- Disease models only: VS improved markers in diabetic, fibrotic, and atherosclerotic mouse models, not in naturally aged animals with these conditions
- Supplement vs. pharmaceutical context: Over-the-counter VS purity, bioavailability, and safety at higher doses are not discussed